Monohydroxyethylrutoside protects against doxorubicin-induced inflammation
Author Information
Author(s): Abou El Hassan M A I, Verheul H M W, Jorna A S, Schalkwijk C, van Bezu J, van der Vijgh W J F, Bast A
Primary Institution: Free University Medical Center
Hypothesis
Can monohydroxyethylrutoside (monoHER) protect against the inflammatory effects of doxorubicin?
Conclusion
Monohydroxyethylrutoside effectively protects human vascular endothelial cells from the inflammatory effects of doxorubicin without affecting its antiproliferative properties.
Supporting Evidence
- Doxorubicin decreased the proliferation of endothelial cells in a concentration-dependent manner.
- MonoHER protected endothelial cells against the cytotoxic effect of doxorubicin.
- Neutrophil adhesion to HUVECs increased significantly after doxorubicin treatment.
Takeaway
This study shows that a substance called monoHER can help protect heart cells from damage caused by a cancer drug called doxorubicin.
Methodology
The study used human vascular endothelial cells (HUVECs) to assess the effects of doxorubicin and monoHER on cell viability, proliferation, and neutrophil adhesion.
Limitations
The study was conducted in vitro, which may not fully represent in vivo conditions.
Participant Demographics
Human vascular endothelial cells were used, isolated from umbilical cord veins.
Statistical Information
P-Value
0.0014
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website